Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL379 Target Snapshot

Hepatitis C virus · ORGANISM · Hepacivirus hominis

12,165Compounds
3,162Assays
51Approved Drugs
18,147.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

Confirm a stable target identifier before relying on this context across project surfaces.

Review focus
Open DB context pending

Confirm a stable target identifier before relying on this context across project surfaces.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Hepatitis C virus as ChEMBL target CHEMBL379. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Hepatitis C virus
ORGANISM · Hepacivirus hominis
As of 2026-09-14
ChEMBL target ID
CHEMBL379
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Hepatitis C virus still has a stable protein naming contract across sources.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelHepatitis C virus
UniProt AccessionN/A

Hepatitis C virus

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Hepatitis C virus.

Review nameHepatitis C virus
OrganismHepacivirus hominis
Clinical Profile

Clinical Phase Distribution

51
Approved
25
Phase III
47
Phase II
11
Phase I
Assay Mix

Activity Type Distribution

IC502,739.0
KI116.0
EC5015,265.0
KD27.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL2023898 11.0 EC50 0.01 Approved
CHEMBL2036969 11.0 EC50 0.01 Preclinical
CHEMBL2036977 11.0 EC50 0.01 Preclinical
CHEMBL3120448 11.0 EC50 0.01 Preclinical
CHEMBL3121843 11.0 EC50 0.01 Preclinical
CHEMBL3121953 11.0 EC50 0.01 Preclinical
CHEMBL3122028 11.0 EC50 0.01 Preclinical
CHEMBL3122033 11.0 EC50 0.01 Preclinical
CHEMBL3127112 11.0 EC50 0.01 Preclinical
CHEMBL3360471 11.0 EC50 0.01 Preclinical
Distribution

pChEMBL Value Distribution

1450
5.0
1499
5.5
1657
6.0
1619
6.5
1819
7.0
1480
7.5
1275
8.0
753
8.5
508
9.0
323
9.5
pChEMBL
Approved Drugs

Approved Drugs

REMDESIVIR
CHEMBL4065616
Approved 2020
GLECAPREVIR
CHEMBL3545363
Approved 2017
GRAZOPREVIR ANHYDROUS
CHEMBL2063090
Approved 2016
ELBASVIR
CHEMBL3039514
Approved 2016
BELINOSTAT
CHEMBL408513
Approved 2014
DACLATASVIR
CHEMBL2023898
Approved 2014
ASUNAPREVIR
CHEMBL2105735
Approved 2014
LEDIPASVIR
CHEMBL2374220
Approved 2014
OMBITASVIR
CHEMBL3127326
Approved 2014
PARITAPREVIR
CHEMBL3391662
Approved 2014
SOFOSBUVIR
CHEMBL1259059
Approved 2013
SIMEPREVIR
CHEMBL501849
Approved 2013
BOCEPREVIR
CHEMBL218394
Approved 2011
TELAPREVIR
CHEMBL231813
Approved 2011
VORINOSTAT
CHEMBL98
Approved 2006
DASATINIB
CHEMBL5416410
Approved 2006
ERLOTINIB
CHEMBL553
Approved 2004
NITAZOXANIDE
CHEMBL1401
Approved 2002
IMIQUIMOD
CHEMBL1282
Approved 1997
GEMCITABINE
CHEMBL888
Approved 1996
RIBAVIRIN
CHEMBL1643
Approved 1985
CYCLOSPORINE
CHEMBL160
Approved 1983
NICLOSAMIDE
CHEMBL1448
Approved 1982
CYTARABINE
CHEMBL803
Approved 1969
HYDROXYZINE
CHEMBL896
Approved 1956
Assay Landscape

Assay Landscape

3,170
Total Assays
8,656
Tested Compounds
3
Assay Types
Functional — 2,982 assays, 8,656 compounds
BAO Format Assays Compounds Avg pChEMBL
organism-based format 2,522 7,319 6.9
cell-based format 379 1,182 7.0
assay format 78 155 6.5
cell-free format 3 0
Binding — 186 assays, 1,171 compounds
BAO Format Assays Compounds Avg pChEMBL
organism-based format 184 1,171 6.7
assay format 1 0
cell-free format 1 0
ADME — 2 assays, 0 compounds
BAO Format Assays Compounds Avg pChEMBL
organism-based format 2 0

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine